Navigation Links
INTAC™ Technology Combats Misuse of Extended Release Drugs
Date:5/15/2012

BEDMINSTER, N.J., May 15, 2012 /PRNewswire/ -- During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012 • Honolulu, HI) Grunenthal will present results from clinical studies utilizing a product based on its INTAC™ formulation technology. INTAC™ is designed to be crush-resistant and to protect intended action of extended release drugs. Applying INTAC™ to prescription opioid drugs is considered an efficient means to combat unintended and intended drug misuse and abuse through tampering with the formulation.

Prescription opioids are at the center of a major public health crisis of misuse and abuse in the United States. Prescription drug abuse is the fastest-growing drug problem in the US and drug overdose death rates have risen steadily in the US[1]. Technological approaches that intend to prohibit or reduce the ability to abuse specific time-release drugs by tampering with the formulation through crushing are therefore an effective means to address the issue.

Dr. Hans-Jurgen Stahlberg, Director and International Clinical Lead at Grunenthal will present data from a clinical development program aimed at demonstrating bioequivalence between a non-tamper resistant originator product and the product utilizing INTAC™ formulation technology (Bridging from Conventional Marketed Extended Release Formulations to New Tamper Resistant Alternatives, poster # 391). The structure and regulatory frame for the study program as well as the results and outcome for physicians and patients will be discussed.

About INTAC™

INTAC™, Grunenthal's tamper resistant formulation technology, is designed to deter various relevant routes of abuse / inadvertent misuse from tablet tampering by imposing a specific mechanical stability to the tablet. This mechanical stability is created by the combination of specific excipients together with a unique manufacturing process. Grunenthal's proprietary INTAC™ approach is established at commercial manufacturing scale and is featured in FDA-approved products which are marketed by US partners. Grunenthal considers its patent protected INTAC™ to be the leading technology for abuse-deterrent and tamper-resistant opioid products. The INTAC™ technology is available for licensing to interested companies for various product opportunities.

About Grunenthal

The Grunenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company to be a leader in therapy innovation. Grunenthal is one of the last five research-oriented pharmaceutical corporations with headquarters based in Germany which sustainably invests in research and development. These investments amounted to about 25 % of revenues in 2011. Grunenthal's research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grunenthal Group has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and approx. 4200 employees are working for the Grunenthal Group worldwide. In 2011, Grunenthal reached estimated revenues of 947 Mio euros. More information: www.grunenthal.com.

[1] Epidemic: Responding to America's Prescription Drug Abuse Crisis. Executive Office of the President of the United States, 2011


'/>"/>
SOURCE Grünenthal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
2. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
3. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
4. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
5. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
9. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2019)... , ... November 15, 2019 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in Columbus, ... experts, facility features and amenities. , According to the Alzheimer’s Association ...
(Date:11/16/2019)... ... November 15, 2019 , ... October 29 article ... any time when more than usual is being consumed – is best done near ... doing so, the sugars and acids found in candy are more likely to be ...
(Date:11/15/2019)... ... , ... JustCBD looks forward to working with Hope For The ... by the military families aboard Marine Corps Base Camp Lejeune, North Carolina. These families ... the past 13 years, Hope For The Warriors has been dedicated to serving those ...
Breaking Medicine Technology:
(Date:11/15/2019)... N.Y. (PRWEB) , ... November 15, 2019 , ... ... of over 100 employers in Newsday’s Top Long Island Workplaces for 2019. The ... , During the selection process, Newsday worked in partnership with Energage to ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... treatments for cancers and other serious diseases, announced it will have 5 poster ... at the upcoming 24th Annual Society for Neuro-Oncology SNO Meeting in Phoenix, beginning ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... most complete business management solution for physical therapy and rehabilitation operators throughout the ... engagement technology with customers in 102 countries, today announces a joint venture to ...
(Date:11/11/2019)... ... November 11, 2019 , ... Thermal Product Solutions, a ... Gruenberg Depyrogenation Sterilizers to the Pharmaceutical Industry. The units will be used ... 280°C with work chamber dimensions of 36” W x 36” D x 53” ...
Breaking Medicine News(10 mins):